West Pharmaceutical Services (WST) Q1 FY26 earnings call

West Pharmaceutical Services reported a strong Q1 FY26, significantly exceeding revenue and EPS expectations, driven by robust HVP components growth across GLP-1 and non-GLP-1 segments. This performance led to an upward revision of full-year organic revenue and adjusted EPS guidance, reflecting continued market momentum and operational efficiencies. The company is navigating commodity cost increases and the SmartDose divestiture while focusing on long-term growth drivers like biologics and Annex 1.